聚乙二醇化重组人粒细胞刺激因子预防乳腺癌剂量密集化疗后的 中性粒细胞减少.

Objective To study the efficacy of pegylated recombinant human granulocyte stimulating factor (PEG-rhG-CSF) in the prevention of neutropenia in breast cancer patients for dose intensive adjuvant chemotherapy and to provide the evidence for the clinical application of PEG-rhG-CSF. Methods 37 women with breast cancer were randomly divided into two groups. The experimental group accepting PEG-rhG-CSF prevention after EC-T chemotherapy and the control group accepting rhG-CSF prevention. The efficiency of PEG-rhG-CSF, the incidence and duration of neutropenia in two groups during six cycles of chemotherapy were monitored. Results 37 patients (22 in the experimental group and 15 in the control group) were enrolled in the clinical observation. The incidence of degree 3 and 4 neutropenia in the experimental group was lower than that in the control group during each chemotherapy cycle, and the difference was statistically significant. The difference between the two groups of time from the end of chemotherapy to the lowest absolute value of neutrophils was not statistically significant (P = 0.51). The difference between the two groups of the duration of degree3 and 4 neutropenia was not statistically significant (P = 0.119).There was no significant difference in the quality of life between the two groups. Conclusion PEG-rhG-CSF can reduce the incidence of degree 3 or 4 neutropenia in breast cancer patients for dose intensive adjuvant chemotherapy and the efficacy is better than rhG-CSF, suggesting that PEG-rhG-CSF has the clinical value. [ABSTRACT FROM AUTHOR]